NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cindy TahlCLO2026-08-0438,800$2.46
$95.41kSell
Bahram ValamehrCEO;Pres2026-08-0443,947$2.46
$108.11kSell
Cindy TahlChief Legal and Compliance Officer2026-05-2025,590$1.88
$48.08kSell
Bahram ValamehrPresident and CEO2026-05-2028,946$1.88
$54.48kSell
Cindy TahlChief Legal and Compliance Officer2026-05-0644,444$1.05
$46.67kBuy
Cindy TahlChief Legal and Compliance Officer2026-05-06122,220$1.32
$161.33kBuy
Robert S. EpsteinDirector2026-05-0525,000$1.69
$42.25kBuy
William H. RastetterDirector2026-05-0525,000$1.69
$42.25kBuy
Cindy TahlChief Legal and Compliance Officer2026-01-0910,589$1.07
$11.28kSell
Bahram ValamehrPresident and CEO2026-01-095,190$1.07
$5.56kSell

1 of 1

FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC22.11%25,768,554$70.09MInsider
Redmile Group LLC11.04%12,872,946$35.01MInstitution
Blackrock Inc8.64%10,068,614$27.39MInstitution
Amir Nashat8.45%9,852,967$26.80MInsider
Polaris Venture Management Co V LLC8.44%9,841,933$26.77MInsider
Redco II Master Fund LP7.70%8,977,624$24.42MInsider
Vanguard Capital Management LLC3.60%4,192,063$11.40MInstitution
Vanguard Portfolio Management LLC3.55%4,134,585$11.25MInstitution
Acadian Asset Management LLC3.53%4,120,200$11.21MInstitution
Two Sigma Investments LP2.97%3,466,786$9.43MInstitution

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE51.89%48.11%Net BuyingNet Selling
TTRX1.55%58.04%Net Buying
SION66.77%33.23%Net SellingNet Selling
IFRX12.81%2.95%
TRDA39.53%60.47%Net SellingNet Selling

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 63.57% institutional shareholders, 58.94% Fate Therapeutics insiders, and 0.00% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 25.77M shares representing 22.11% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $64.94M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.